Loading...
PARADIGM-2: two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status.
Fulton, B Short, S James, A Nowicki, S McBain, Catherine A Jefferies, S Kelly, C Stobo, J Morris, A Williamson, A
Fulton, B
Short, S
James, A
Nowicki, S
McBain, Catherine A
Jefferies, S
Kelly, C
Stobo, J
Morris, A
Williamson, A
Citations
Altmetric:
Abstract
Glioblastoma has a dismal prognosis and molecular targeted agents have failed to improve outcomes to date. PARADIGM-2 is a phase I dose escalation study evaluating olaparib plus radiotherapy ± temozolomide in newly diagnosed glioblastoma, using MGMT methylation status to stratify patients and inform treatment schedules.
Description
Date
2018-01
Publisher
Collections
Files
Keywords
Type
Article
Citation
PARADIGM-2: two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status. 2018, 8: 12-16 Clin Transl Radiat Oncol